Ralph D'Agostino to Prostatic Hyperplasia
This is a "connection" page, showing publications Ralph D'Agostino has written about Prostatic Hyperplasia.
Connection Strength
0.414
-
Wallner LP, DiBello JR, Li BH, Van Den Eeden SK, Weinmann S, Ritzwoller DP, Abell JE, D'Agostino R, Loo RK, Aaronson DS, Horwitz RI, Jacobsen SJ. The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality. Urology. 2018 Sep; 119:70-78.
Score: 0.158
-
Wallner LP, DiBello JR, Li BH, Van Den Eeden SK, Weinmann S, Ritzwoller DP, Abell JE, D'Agostino R, Loo RK, Aaronson DS, Richert-Boe K, Horwitz RI, Jacobsen SJ. 5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia. Mayo Clin Proc. 2016 Dec; 91(12):1717-1726.
Score: 0.141
-
Hassan S, Karpova Y, Flores A, D'Agostino R, Danhauer SC, Hemal A, Kulik G. A pilot study of blood epinephrine levels and CREB phosphorylation in men undergoing prostate biopsies. Int Urol Nephrol. 2014 Mar; 46(3):505-10.
Score: 0.114